MAOB and Parkinson disease: Dopamine agonists (DAGs), catechol-O methyltransferase (COMT) inhibitors, as well as monoamine oxidase (MAO)-B inhibitors, possess entrenched spots in the management of PD in addition to levodopa8–11.